Lovotibeglogene autotemcel (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lovotibeglogene autotemcel" in English language version.

refsWebsite

Global rank English rank

4web.archive.org

1^st place

4nih.gov

4^th place

2fda.gov

447^th place

338^th place

2doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

1nature.com

234^th place

397^th place

1businesswire.com

615^th place

407^th place

1cbsnews.com

108^th place

80^th place

1icer.org

low place

1handle.net

102^nd place

76^th place

businesswire.com

"Bluebird Bio Announces FDA Approval of Lyfgenia (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events" (Press release). Bluebird Bio. 8 December 2023. Retrieved 9 December 2023 – via Business Wire.

cbsnews.com

https://www.cbsnews.com/newyork/news/sickle-cell-anemia-cure-new-york/

doi.org

Kanter, Julie; Thompson, Alexis A.; Pierciey, Francis J.; Hsieh, Matthew; Uchida, Naoya; Leboulch, Philippe; et al. (January 2023). "Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB -206 study". American Journal of Hematology. 98 (1): 11–22. doi:10.1002/ajh.26741. PMC 10092845. PMID 36161320. S2CID 252544370.
Sheridan, Cormac (21 November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

fda.gov

"Lyfgenia". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 9 December 2023. This article incorporates text from this source, which is in the public domain.
"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 8 December 2023. This article incorporates text from this source, which is in the public domain.

handle.net

hdl.handle.net

World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.

icer.org

"ICER Publishes Final Evidence Report on Gene Therapies for Sickle Cell Disease". Institute for Clinical and Economic Review. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

nature.com

Sheridan, Cormac (21 November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kanter, Julie; Thompson, Alexis A.; Pierciey, Francis J.; Hsieh, Matthew; Uchida, Naoya; Leboulch, Philippe; et al. (January 2023). "Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB -206 study". American Journal of Hematology. 98 (1): 11–22. doi:10.1002/ajh.26741. PMC 10092845. PMID 36161320. S2CID 252544370.
Sheridan, Cormac (21 November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

dailymed.nlm.nih.gov

"Lyfgenia- lovotibeglogene autotemcel suspension". DailyMed. 22 December 2023. Retrieved 30 December 2023.

ncbi.nlm.nih.gov

Kanter, Julie; Thompson, Alexis A.; Pierciey, Francis J.; Hsieh, Matthew; Uchida, Naoya; Leboulch, Philippe; et al. (January 2023). "Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB -206 study". American Journal of Hematology. 98 (1): 11–22. doi:10.1002/ajh.26741. PMC 10092845. PMID 36161320. S2CID 252544370.

semanticscholar.org

api.semanticscholar.org

Kanter, Julie; Thompson, Alexis A.; Pierciey, Francis J.; Hsieh, Matthew; Uchida, Naoya; Leboulch, Philippe; et al. (January 2023). "Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB -206 study". American Journal of Hematology. 98 (1): 11–22. doi:10.1002/ajh.26741. PMC 10092845. PMID 36161320. S2CID 252544370.
Sheridan, Cormac (21 November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.

web.archive.org

"Lyfgenia". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 9 December 2023. This article incorporates text from this source, which is in the public domain.
"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 8 December 2023. This article incorporates text from this source, which is in the public domain.
Sheridan, Cormac (21 November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.
"ICER Publishes Final Evidence Report on Gene Therapies for Sickle Cell Disease". Institute for Clinical and Economic Review. Archived from the original on 4 December 2023. Retrieved 4 December 2023.